BRONCHOLITIC THERAPY IN BRONCHIAL ASTHMA: PROPER CHOICE



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In this article the problems of improving the control of bronchial asthma through optimization of bronchodilator therapy are discussed. Cholinergic mechanisms in the pathogenesis of asthma and the possibilities of use of long-acting m-anticholinergic - tiotropium (via liquid inhaler R espimat) - in the treatment of this disease are shown. Pharmacological properties of bronchodilators are discussed to identify the main groups of patients who need tiotropium therapy.

Full Text

Restricted Access

About the authors

O M Kurbacheva

Institute of Immunology

Email: kurbacheva@gmail.com
Moscow, Russia

S A Polner

Institute of Immunology

Moscow, Russia

D S Smirnov

Institute of Immunology

Moscow, Russia

References

  1. To T., Stanojevic S., Moores G. et al. Global Asthma Prevalence in Adults. BMC Public Health. 2012, v. 12, р. 204-209.
  2. Архипов В.В. Новые перспективы повышения контроля над бронхиальной астмой. От науки к практике. Атмосфера. Практическая пульмонология. 2014, № 1, с. 2-7.
  3. Rabe K.F., Vermeire A.P., Soriano J.B. et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000, v. 16, р. 802-807.
  4. Partridge M.R., Myrseth S.E., Busse W.W. et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med. 2006, v. 6, р. 13-20.
  5. Demoly P., Annunziata K., Gubba E. et al. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 2012, v. 21, р. 66-77.
  6. Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011, № 6, с. 87-93.
  7. Исследования ГФК-Русь 2012-2013. http://www.evrika.ru/ show/6625/ company_feed.
  8. Milgrom H., Bender B., Ackerson L. et al. Noncompliance and treatment failure in children with asthma. J. Allergy Clin. Immunol. 1996, v. 98, р. 1051-1057.
  9. Rootmensen G.N., Jansen H.M., R.J. de Haan et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J. Aerosol Med. Pulm. Drug Deliv. 2010, v. 23, р. 323-328.
  10. Humbert M., Holgate S., Boulet L.P. et al. Asthma control or severity: that is the question. Allergy. 2007, v. 62, р. 95-101.
  11. Israel E., Vernon M., Jean G. Ford et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet. 2004, v. 364, р. 1505-1512.
  12. Ikeda A., Nishimura K., Koyama H. et al. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax. 1995, v. 50, р. 62-66.
  13. Rodrigo G., Rodrigo C., Burschtin O. et al. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am. J. Med. 1999, v. 107, р. 363-370.
  14. Plotnik L.H. Ducharme F.M. Should inhaled anticholinergics be added to b2-agonists for treating acute childhood and adolescent asthma? A systematic review. Br. Med. J. 1998, v. 317, р. 971-977.
  15. Lanes S.F., Garrett J.E., Fitzgerald J.M. et al. The effect of adding ipratropium bromide to salbutamol in the treatment ofacute asthma: a pooled analysis ofthree trials. Chest. 1998, v. 114, р. 366-372.
  16. Rodrigo G., Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multipledose protocol of ipratropium bromide plus albuterol in the emergency department. Am. J. Respir. Crit. Care Med. 2000, v. 161, р. 1862-1868.
  17. Shelley R., Thomas M.O., Edwin E.S. Meta-analysis: respiratory tolerance to regular b2-agonist use in patients with asthma. Ann. Intern. Med. 2004, v. 140, р. 802-808.
  18. Donohue J.F. Therapeutic responses in asthma and COPD: bronchodilators. Chest. 2002, v. 122, р. 47-55.
  19. Giannini В., Di Franco A., Bacci E. et al. Tolerance to the protective effect of salmeterol on allergen challenge can be partially restored by the withdrawal of salmeterol regular treatment. Chest. 2001, v. 119, р. 1671-1677.
  20. Aubdool A.A., Brain S.D. Neurovascular aspects of skin neurogenic inflammation. J. Investig. Dermatol. Symp. Proc. 2011, v. 15, р. 33-39.
  21. Raemdonck K., de Alba J., Birrell M. A. et al. Original article: A role for sensory nerves in the late asthmatic response. Thorax. 2012, v. 67, р. 19-24.
  22. Ненашева Н.М., Новые возможности достижения контроля астмы с помощью тиотропия бромида. Эффективная фармакотерапия. Пульмонология и оториноларингология. 2014, № 2, с. 28-34.
  23. Nadel J.A., Bames P.J. Autonomic regulation of the airways. Annu. Rev. Med. 1984, v. 35, р. 451-467.
  24. Disse B., Reichl R., Speck G. et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993, v. 52, р. 537-544.
  25. Joos G.F. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch. Chest. Dis. 2000, v. 55, р. 411-414.
  26. Haddad el B., Rousell J. Regulation of the expression and function of the M2 muscarinic receptor. Trends Pharmacol. Sci. 1998, v. 19, р. 322-327.
  27. Ayala L.E., Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest. 1989, v. 96, р. 1285-1291.
  28. Haddad E.B., Mak J.C., Barnes P.J. Characterization of [3H] Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol. Pharmacol. 1994, v. 45, р. 899-907.
  29. Barnes PJ. Tiotropium bromide. Expert Opin. Investig. Drugs. 2001, v. 10, р. 733-740.
  30. Heung-Woo Park. The role of tiotropium in the management of asthma. Asia Pac. Allergy. 2012, v. 2, р. 109-114.
  31. ZuWallack A.R., ZuWallack R.L. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Expert. Opin. Phar- macother. 2004, v. 5, р. 1827-1835.
  32. Disse B., Speck G.A., Rominger K.L. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999, v. 64, р. 457-464.
  33. Gross N.J. Tiotropium bromide. Chest. 2004, v. 126, р. 1946-1953.
  34. Yohannes A.M., Connolly M.J., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. COPD. 2013, v. 8, р. 117-125.
  35. Park H.W, Yang M.S., Park C.S. et al. Additive role oftiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009, v. 64, р. 778-783.
  36. Peters S.P., Kunselman S.J., Icitovic N. еt al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 2010, v. 363, р. 1715-1726.
  37. Kerstjens H.A., Disse B., Schroder-Babo W. et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J. Allergy. Clin. Immunol. 2011, v. 128, р. 308-314.
  38. Bateman E.D., Kornmann O., Schmidt P. et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J. Allergy. Clin. Immunol. 2011, v. 128, р. 315-322.
  39. Kerstjens H.A., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012, v. 367, р. 1198-1207.
  40. Adams K.S., Lowe D.K. Tiotropium for adults with inadequately controlled persistent asthma. Ann. Pharmacother. 2013, v. 47, р. 117-123.
  41. Panning C.A., DeBisschop M. Tiotropium: an inhaled long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy. 2003, v. 23, р. 183-189.
  42. Yohannes A.M., Connoly M. J., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. Chron. Obstruct. Pulmon. Dis. 2013, v. 8, р.117-125.
  43. Tashkin D.P. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr. Opin. Pulm. Med. 2010, v. 16, р. 97-105.
  44. Hochrainer D., Holz H., Kreher C. et al. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ Inhaler and pressurized metered dose inhalers. J. Aerosol Med. 2005, v. 18, р. 273-282.
  45. Pitcairn G., Reader S., Pavia D. et al. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler® Dry Powder Inhaler. J. Aerosol Med. 2005, v. 18, р. 264-272.
  46. Barczok M. Presented at VIII Deutsches Aerosol Therapie Seminar, Marburg, Germany. November 2003.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2014



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies